Literature DB >> 2067740

Radiolabelled monoclonal antibodies in oncology. III. Radioimmunotherapy.

K E Britton1, S J Mather, M Granowska.   

Abstract

The requirements, problems and progress of radioimmunotherapy in the management of certain malignancies are described. The future prospects using a two- or three-stage approach are promising.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2067740

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN： 0143-3636            Impact factor:   1.690


  4 in total

Review 1.  Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?

Authors:  J F Chatal; P Peltier; M Bardiès; A Chétanneau; P Thedrez; A Faivre-Chauvet; J F Gestin
Journal:  Eur J Nucl Med       Date:  1992

2.  Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy.

Authors:  R W Howell; S M Goddu; D V Rao
Journal:  Med Phys       Date:  1998-01       Impact factor: 4.071

3.  Radioimmunotherapy: no news from the newcomer.

Authors:  A M Mello; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

4.  Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies.

Authors:  P Riva; A Arista; C Sturiale; V Tison; S Lazzari; G Franceschi; A Spinelli; M Casi; G Sarti; F Campori
Journal:  Cell Biophys       Date:  1994
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.